Data on Early Onset of Efficacy for Oral OTEZLA® (apremilast) in Active Psoriatic ...

ACTIVE trial in biologic-naïve patients met its primary endpoint, demonstrating significant improvement in ACR20 response rate at week 16 with OTEZLA versus placebo

Improvements in ACR20 and other measures of disease seen as early as week 2

ACR20 response rate increased from 38 percent at week 16 to 67 percent at week 52 for patients who received OTEZLA therapy from baseline